PFE Pfizer Inc.

Pfizer Launches New “Moodivator” App to Help Support, Encourage and Motivate People with Depression

Today, Pfizer Inc announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7%) experience at least one major depressive episode in any given year.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160913005932/en/

Living with depression can feel isolating, overwhelming and impact all aspects of a person’s life. An increasing number of patients, especially those who suffer from chronic conditions like depression, are turning to their smartphones to supplement treatment they receive. The new app aims to provide ongoing motivation in a simple and portable way. Moodivator is designed to help complement the treatment patients receive by allowing them to track their mood, set goals and establish routines that can help support them in their daily life. The Moodivator app is free and available to download for iPhones from the Apple App Store at https://itunes.apple.com/us/app/moodivator/id1103213442?ls=1&mt=8.

Treatment for depression often includes a number of approaches such as talk therapy, medication, peer support and a personal wellness plan – however, it may be challenging for some patients to adhere to their treatment. Fortunately, advances in technology like Moodivator are offering new ways to approach health management, encouraging them to take a more active role in managing their condition. In fact, a 2014 survey found that 70% of patients being treated for a mental health disorder say they want to use a mobile application to monitor their mental health on a daily basis.

“As awareness of the magnitude and severity of depression continues to mount, technology like the Moodivator app represents a new and exciting frontier for helping people with depression. The option to set, track and achieve personal goals in the Moodivator app ties in nicely with cognitive behavioral therapy techniques that I use often with my patients,” said Susan Kornstein, MD, professor of psychiatry at Virginia Commonwealth University School of Medicine, who helped consult on the app's design. “The opportunity for patients to track and export their mood and goal progress in easy-to-read charts is also very useful, because the progress can then be shared with doctors to help inform care decisions.”

Mobile apps offer the potential to help address key barriers to accessing real-time support for depression. Designed to fit into patients' schedules and lifestyles, the Moodivator app uses a simple and accessible interface with customizable features. Patients also receive encouraging and inspirational messages in the app to help motivate them as they work to manage their depression. This app includes a number of simple features that leverage some best principles in managing depression:

  • Goal setting: Ability to create customizable, manageable goals with clear action steps to help patients achieve them, which can be made across one or more categories, including work, home and family or social activities. Goals can be adjusted over time and turned into helpful habits as part of an ongoing routine.
  • Mood tracking: A simple scale lets patients track how they are feeling when it is convenient for them, whether multiple times a day or sporadically. Mood tracking is an important tool for improving patients’ emotional self-awareness. Tracking mood through a mobile app also offers the convenience of real-time reporting, which can make it easier to identify long-term patterns with their care team.
  • Sharing results: Opportunity for patients to share their goal progress with their care team, showcasing their progress through clear charts.

The Moodivator app is not a treatment for depression. All patients should work with their doctor to determine which course of treatment is right for them, and even when patients start to feel better, they should continue their therapy and work closely with their doctor until they reach an agreement to conclude the treatment plan. This app includes information about a prescription treatment option for depression.

About Pfizer Inc: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

PP-PRQ-USA-0522

Downloadable Assets:

EN
13/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pfizer Inc.

Pelham Smithers
  • Pelham Smithers

PSA Healthcare / Pharma: Pfizer GLP-1 Drug Failure Puts Light on Upcom...

Pelham Smithers sees the Pfizer news as positive for Chugai and also draws attention to Nxera.

 PRESS RELEASE

Pfizer Invites Public to View and Listen to Webcast of April 29 Confer...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to re...

 PRESS RELEASE

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Hea...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion will be made available on our web site at within 24 hours after the end of the live discussion a...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Pfizer Inc: 1 director

Two Directors at Pfizer Inc sold/bought 19,764 shares at between 0.000USD and 25.650USD. The significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch